DDIAS may be a potential therapeutic target for tamoxifen-resistant breast cancer since the inhibition of PSPC1 or SCFD2 reduces in vivo tumor development in tamoxifen-resistant breast cancer. The gene discussed is PSPC1; the disease is breast cancer.